Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Yael L. Maxwell

October 09, 2023

News Daily News

Hypertension Drug Effects Differ From Person to Person, PHYSIC Trial Shows

L.A. McKeown

April 12, 2023

News Daily News

More AF Surveillance Needed in Chemotherapy Trials, Meta-analysis Hints

L.A. McKeown

April 06, 2023

News Conference News ACC 2023

Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin

Yael L. Maxwell

March 13, 2023

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Daily News

Statins Positively Alter Coronary Plaque Composition

Michael O'Riordan

August 23, 2021

News Daily News

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

L.A. McKeown

June 17, 2020

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

More Research Supports Use of Aspirin Alone to Prevent VTE After Knee Replacement Surgery

L.A. McKeown

October 18, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

Advertisement

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Hypertension Drug Effects Differ From Person to Person, PHYSIC Trial Shows

More AF Surveillance Needed in Chemotherapy Trials, Meta-analysis Hints

Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin

Heterozygous FH Diagnosed Late, Remains Undertreated

Statins Positively Alter Coronary Plaque Composition

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

More Research Supports Use of Aspirin Alone to Prevent VTE After Knee Replacement Surgery

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content